Changes in insulin receptor signaling underlie neoadjuvant metformin administration in breast cancer: a prospective window of opportunity neoadjuvant study
This prospective single-arm “window of opportunity” trial evaluated the biological effects of short-term metformin administration in 39 non-diabetic women with early-stage breast cancer. Patients received 500 mg of metformin three times daily for at least two weeks between diagnostic biopsy and surgery. Metformin treatment led to significant reductions in tumor
June 26, 2025
No Comments